Wedbush Forecasts Higher Earnings for Vera Therapeutics

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Wedbush boosted their FY2027 earnings per share (EPS) estimates for Vera Therapeutics in a note issued to investors on Monday, June 2nd. Wedbush analyst L. Chico now expects that the company will post earnings of ($2.04) per share for the year, up from their previous estimate of ($3.14). Wedbush has a "Neutral" rating and a $26.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' FY2028 earnings at $0.12 EPS and FY2029 earnings at $1.77 EPS.

Other research analysts also recently issued reports about the company. HC Wainwright reaffirmed a "buy" rating and set a $85.00 price target (up from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. JPMorgan Chase & Co. lowered their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. Guggenheim reaffirmed a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Cantor Fitzgerald lowered their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $65.00.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA traded down $7.93 during midday trading on Thursday, reaching $22.70. 12,635,089 shares of the company's stock traded hands, compared to its average volume of 926,133. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -8.70 and a beta of 1.13. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.61. The stock has a 50 day moving average of $22.40 and a 200 day moving average of $31.39.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period last year, the company earned ($0.56) earnings per share.

Institutional Trading of Vera Therapeutics

Several institutional investors have recently made changes to their positions in the business. Huntington National Bank bought a new position in Vera Therapeutics during the fourth quarter valued at approximately $26,000. AlphaQuest LLC bought a new position in Vera Therapeutics during the fourth quarter valued at approximately $34,000. GF Fund Management CO. LTD. bought a new position in Vera Therapeutics during the fourth quarter valued at approximately $56,000. Quarry LP boosted its stake in Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $60,000 after buying an additional 500 shares during the last quarter. Finally, KBC Group NV boosted its stake in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after buying an additional 1,387 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.